12th International Congress on Myeloproliferative Neoplasms

 

12th International Congress on Myeloproliferative Neoplasms
N

Moving Beyond JAKi: Ruxolitinib Failure, Newly Approved and in Development JAKi, & Novel Therapies (JAKi Combo & Novel Agents)

By 12th International Congress on Myeloproliferative Neoplasms FEATURING Naveen Pemmaraju
By 12th International Congress on Myeloproliferative Neoplasms FEATURING Naveen Pemmaraju
104 views
November 12, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Latest Advances in Myeloproliferative Neoplasms
19:58
12th International Congress on Myeloproliferative Neoplasms

How Should We Treat Children w/ MPN: No Guidelines on Cytoreduction …

Feat. N. Kucine
22:49
12th International Congress on Myeloproliferative Neoplasms

Old and New Myelofibrosis (MF) Classifications, When to Consider Tra…

Feat. H. Deeg
28:48
12th International Congress on Myeloproliferative Neoplasms

Introduction to Hypoxia and Erythropoiesis in the Context of High Al…

Feat. J. Prchal
26:03
12th International Congress on Myeloproliferative Neoplasms

Moving Beyond JAKi: Ruxolitinib Failure, Newly Approved and in Devel…

Feat. N. Pemmaraju
28:30
12th International Congress on Myeloproliferative Neoplasms

Is There a Role of Transplantation for CML in the Era of TKIs?

Feat. K. Van Besien
16:32
12th International Congress on Myeloproliferative Neoplasms

What Are the Risk Factors for Accelerated/Blast Phase MPN and the Ou…

Feat. O. Odenike
08:25
12th International Congress on Myeloproliferative Neoplasms

What is the Molecular Landscape of Blast Phase MPN and the Implicati…

Feat. O. Odenike
06:52
12th International Congress on Myeloproliferative Neoplasms

Targeting Dysregulated Iron Metabolism in Polycythemia Vera (PV) Pat…

Feat. R. Hoffman
08:25
12th International Congress on Myeloproliferative Neoplasms

Therapeutic Options for Treating MPNs are Finally Expanding: Targeti…

Feat. R. Hoffman
11:27
12th International Congress on Myeloproliferative Neoplasms

Therapeutic Options for MPNs are Finally Expanding: Immunotherapies …

Feat. R. Hoffman
17:00
12th International Congress on Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-F…

Feat. R. Silver
07:54
12th International Congress on Myeloproliferative Neoplasms

Update on Long Acting Interferons in MPN: Who Should Be Treated, Who…

Feat. H. Gisslinger
25:17
12th International Congress on Myeloproliferative Neoplasms

Wrangling the MPN-Related Symptom Burden: Specific Symptoms and Etio…

Feat. R. Scherber
26:23
12th International Congress on Myeloproliferative Neoplasms

Update on Myeloid Variant Hypereosinophilia Syndrome: Clinical Subty…

Feat. A. Klion
30:14
12th International Congress on Myeloproliferative Neoplasms

Tales from the Clinic on Essential Thrombocytosis: No Therapy for As…

Feat. J. Spivak
13:55
12th International Congress on Myeloproliferative Neoplasms

Review of JAK2V617F and the Concept of the VAF

Feat. A. Moliterno
20:40
12th International Congress on Myeloproliferative Neoplasms

Review of JAK2V617F VAF Associations in the Context of MPN and CHIP:…

Feat. A. Moliterno